OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS

Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV. Materials and method: A total of 57 adults with HCV infection who initiated treatment DAA were included in this study. Baseline, 4 weeks and 12 weeks data including clinical characteristics, laboratory results and adverse events (AEs) were recorded. Results: One patient left treatment at the second week. The majority of patients were female 33 (57.9 %) and HCV GT1b (80.7%). Of the patients, 43 (75.4 %) patients were treatment experienced with pegylated interferon +/- RBV and 14 (25.6%) patients were naive. Ten (17.5%) patients had liver cirrhosis, 3 patients renal insufficiency, 7 patients diabetes mellitus, and 6 patients hypertension. Mean baseline ALT and HCV RNA levels was 48.58 +/- 25.8 U/L and 2857661 +/- 7231938 IU/ml, respectively. At the end of the week 4, one patient had >15 IU/mL HCVRNA level, HCVRNA was negative in remaining patients and mean ALT levels was 34.7 +/- 17.01 U/L. Three (5.3%) patient had AEs. At the end of the week 12, HCVRNA was negative in all patients, mean ALT levels was 29.3 +/- 12.2 U/L, 8 (14%) patients had AEs. Conclusion: DAA was a safe and effective therapy with 100% SVR rate and low treatment discontinuation rate (1.7 %) in patients with HCV GT1, GT1a and GT1b. This was well tolerated and efficient treatment aproach in patients with liver cirrhosis, renal insufficiency, diabetes mellitus, and hypertension.